Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BIRB-796 + Tozasertib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BIRB-796 | Doramapimod|BIRB796|BIRB 796 | p38 MAPK Inhibitor (Pan) 3 | Doramapimod (BIRB-796) is an oral inhibitor of P38 MAPK that enhances cytotoxicity of other anti-tumor agents (PMID: 17173546, PMID: 27082306). | |
Tozasertib | MK-0457|VX-680 | AURK Inhibitor (Pan) 12 BCR-ABL Inhibitor 32 | Tozasertib (VX-680) is a pan-AURK inhibitor with increased potency against Aurora kinase A (AURKA), and has additional activity against BCR-ABL, potentially resulting in decreased tumor growth (PMID: 14981513, PMID: 22772060, PMID: 32017040). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|